1.296 articles found

Autophagy Deficits Underly Selective Neuronal Vulnerability to Alpha Synuclein Fibrils in Alzheimer’s and Parkinson’s iPSC Derived Neurons

Abey A, Ng B, Heon‐Roberts R, Carlyle B, Bengoa‐Vergniory N, Wade‐Martins R.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01

Characterization and Evaluation of Alpha‐Synuclein Aggregates: Unveiling Their Potential as a Biomarker for Parkinson's Disease (PD)

Debarnot C, Challagundla M, Kleinert C, Schulz M, Henn C, Boehm N, Richter M.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01

Serum Alpha‐Synuclein and Inflammatory Markers profile in an Egyptian Alzheimer’s and Parkinson’s Diseases patients: A Pilot Study

Heikal S.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01

MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity.

Jensen NM, Fu Y, Betzer C, Li H, Elfarrash S, Shaib AH, Krah D, Vitic Z, Reimer L, Gram H, Buchman V, Denham M, Rizzoli SO, Halliday GM, Jensen PH.

NPJ Parkinsons Dis · 2024-11-29

DOI: 10.1038/s41531-024-00841-9PMID: 39613827

Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects.

Eo H, Kim S, Jung UJ, Kim SR.

J Clin Med · 2024-11-28

DOI: 10.3390/jcm13237243PMID: 39685702

Alpha-synuclein Fibrils Inhibit Activation of the BDNF/ERK Signaling Loop in the mPFC to Induce Parkinson's Disease-like Alterations with Depression.

Ma Z, Xu Y, Lian P, Wu Y, Liu K, Zhang Z, Tang Z, Yang X, Cao X.

Neurosci Bull · 2024-11-28

DOI: 10.1007/s12264-024-01323-xPMID: 39609371

The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons.

Jones-Tabah J, He K, Karpilovsky N, Senkevich K, Deyab G, Pietrantonio I, Goiran T, Cousineau Y, Nikanorova D, Goldsmith T, Del Cid Pellitero E, Chen CX, Luo W, You Z, Abdian N, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Dupré N, Miliukhina I, Timofeeva A, Emelyanov A, Pchelina S, Greenbaum L, Hassin-Baer S, Alcalay RN, Milnerwood A, Durcan TM, Gan-Or Z, Fon EA.

Mol Neurodegener · 2024-11-25

DOI: 10.1186/s13024-024-00779-9PMID: 39587654

Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson's disease.

Hallbeck M, Ekmark-Lewén S, Kahle PJ, Ingelsson M, Reyes JF.

iScience · 2024-11-23

DOI: 10.1016/j.isci.2024.111448PMID: 39720536

Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein-An In Silico and Experimental Approach to Parkinson's Disease.

Frantzeskos SA, Biggs MA, Banerjee IA.

Biomimetics (Basel) · 2024-11-18

DOI: 10.3390/biomimetics9110705PMID: 39590277

Parkinsonian Syndrome Diagnosed via Novel Alpha-Synuclein Skin Biopsy in a Patient Presenting With Catatonic Symptoms.

Biaggi N, Torres A, Verzura ML, Cruz J, Suarez R.

Cureus · 2024-11-11

DOI: 10.7759/cureus.73441PMID: 39669866

Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson's disease overexpressing human alpha synuclein.

Massaro Cenere M, Tiberi M, Paldino E, D'Addario SL, Federici M, Giacomet C, Cutuli D, Matteocci A, Cossa F, Zarrilli B, Casadei N, Ledonne A, Petrosini L, Berretta N, Fusco FR, Chiurchiù V, Mercuri NB.

NPJ Parkinsons Dis · 2024-11-05

DOI: 10.1038/s41531-024-00824-wPMID: 39500895

Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses.

Mantovani E, Martini A, Dinoto A, Zucchella C, Ferrari S, Mariotto S, Tinazzi M, Tamburin S.

NPJ Parkinsons Dis · 2024-11-02

DOI: 10.1038/s41531-024-00823-xPMID: 39488513